Equol level regulator
US-9080197-B2 · Jul 14, 2015 · US
Equol concentration increasing agent containing psicose as active ingredient
US9839647B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9839647-B2 |
| Application number | US-201615209266-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 13, 2016 |
| Priority date | Nov 30, 2011 |
| Publication date | Dec 12, 2017 |
| Grant date | Dec 12, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a processed food composition containing, as an active ingredient, psicose, which is a saccharide having the function of stimulating a daidzein conversion into equol by an intestinal microorganism in the human body.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for increasing equol production in a subject in need thereof, comprising administering to the subject in need thereof psicose at a suitable dose and at least one substance selected from the group consisting of diadzein, glycoside of diadzein, and dihydrodaidzein, thereby increasing equol production in said subject. 2. The method of claim 1 , wherein the subject has a menopausal disorder, osteoporosis, hyperlipidemia, atherosclerosis, breast cancer, prostate cancer, or premenstrual syndrome. 3. The method of claim 1 , wherein psicose is administered at a dose of 0.1 mg to 100 g per day. 4. The method of claim 1 , wherein psicose is administered at a dose of 50 mg to 50 g per day.
Assignees
Inventors
Classifications
Oestrogens · CPC title
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title
Antineoplastic agents · CPC title
Antihyperlipidemics · CPC title
Bacteria (therapeutic use of a bacterial protein A61K38/00) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9839647B2 cover?
- The present invention relates to a processed food composition containing, as an active ingredient, psicose, which is a saccharide having the function of stimulating a daidzein conversion into equol by an intestinal microorganism in the human body.
- Who is the assignee on this patent?
- Cj Cheiljedang Corp
- What technology area does this patent fall under?
- Primary CPC classification A61K31/7004. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).